Associated Papers
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
Baars B et al.
Molecular Cancer Research : Mcr, 2026
KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges.
Vitiello PP et al.
Cancers, 2025
Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis.
Jiang Y et al.
Npj Precision Oncology, 2025
KRAS Mutations in Colorectal Adenocarcinoma: Incidence and Association with Histological Features with Particular Reference to Gly12Asp in a Multicenter GIPAD Real-World Study.
Parente P et al.
Cancers, 2025
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.
Marasco M et al.
Cancer Discovery, 2025
QM/MM study reveals novel mechanism of KRAS and KRASG12R catalyzed GTP hydrolysis.
Yan X et al.
International Journal of Biological Macromolecules, 2025
Correlation of PD-L1 and HIF-1 Alpha Expression with KRAS Mutation and Clinicopathological Parameters in Non-Small Cell Lung Cancer.
Er Özilhan S et al.
Current Issues in Molecular Biology, 2025
Role of silent mutations in KRAS -mutant tumors.
Lu J et al.
Chinese Medical Journal, 2025
Genomic landscape and comparative analysis of tissue and liquid-based NGS in Taiwanese anaplastic thyroid carcinoma.
Yeh CN et al.
Npj Precision Oncology, 2025
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.
Norton C et al.
Jama Network Open, 2025
Pharmacological restoration of GTP hydrolysis by mutant RAS.
Cuevas-Navarro A et al.
Nature, 2025
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.
Urtecho SB et al.
Lung Cancer (amsterdam, Netherlands), 2025
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer.
Wang X et al.
Hgg Advances, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M et al.
Nature, 2024
A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
Wu H et al.
Cancer Medicine, 2024
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Shin DH et al.
Experimental & Molecular Medicine, 2023
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Saltos AN et al.
Lung Cancer (amsterdam, Netherlands), 2023
RAS-targeted cancer therapy: Advances in drugging specific mutations.
Liu C et al.
Medcomm, 2023
A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
Sugimoto A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.
Jacobsen IC et al.
Acta Oncologica (stockholm, Sweden), 2022
A New View of Activating Mutations in Cancer.
Nussinov R et al.
Cancer Research, 2022
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets.
Rocca A et al.
Cancers, 2022
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer.
Ricciuti B et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2022
Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma.
Xiang C et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
The Potency of a KRAS Silent Variant.
Molina-Arcas M et al.
The New England Journal of Medicine, 2022
The Genomics of Colorectal Cancer in Populations with African and European Ancestry.
Myer PA et al.
Cancer Discovery, 2022
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
Ricciuti B et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Targeting KRAS G12C mutation in lung adenocarcinoma.
Rohatgi A et al.
Lung Cancer (amsterdam, Netherlands), 2022
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers.
Kobayashi Y et al.
Nature, 2022
The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients.
Yang Y et al.
Translational Lung Cancer Research, 2022
Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.
Zhou SL et al.
Jama Surgery, 2022
The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors.
Gebregiworgis T et al.
Nature Communications, 2021
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes.
Varghese AM et al.
Journal of the National Cancer Institute, 2021
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo.
Foggetti G et al.
Cancer Discovery, 2021
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma.
Jiao XD et al.
Translational Lung Cancer Research, 2021
Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer.
Wang X et al.
Annals of Translational Medicine, 2021
Bringing Structural Implications and Deep Learning-Based Drug Identification for KRAS Mutants.
Mehmood A et al.
Journal of Chemical Information and Modeling, 2021
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma.
Frost N et al.
Translational Lung Cancer Research, 2021
The Prevalence and Concurrent Pathogenic Mutations of KRAS G12C in Northeast Chinese Non-small-cell Lung Cancer Patients.
Liu Y et al.
Cancer Management and Research, 2021
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Layeghi-Ghalehsoukhteh S et al.
Scientific Reports, 2020
The Clinical Significance of RAS, PIK3CA, and PTEN Mutations in Non-Small Cell Lung Cancer Using Cell-Free DNA.
Chang WJ et al.
Journal of Clinical Medicine, 2020
The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients.
Lin Q et al.
Journal of Translational Medicine, 2019
Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer.
Wiesweg M et al.
Oncogene, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction.
Sung JS et al.
Oncotarget, 2017